Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?

Expert Opin Investig Drugs. 2005 Mar;14(3):339-42. doi: 10.1517/13543784.14.3.339.
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Alcoholism / drug therapy
  • Alcoholism / physiopathology
  • Animals
  • Humans
  • Obesity / drug therapy
  • Obesity / physiopathology
  • Piperidines / chemistry
  • Piperidines / pharmacology*
  • Piperidines / therapeutic use
  • Pyrazoles / chemistry
  • Pyrazoles / pharmacology*
  • Pyrazoles / therapeutic use
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Receptor, Cannabinoid, CB1 / physiology
  • Rimonabant

Substances

  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Rimonabant
  • surinabant